EUVIMEDEUVIMED entdecken
VergleichsstudieEvaluationsstudie

Performance Evaluation of 2 FDA-Approved Fentanyl Immunoassays against LC-MS/MS Reference

Leah Militello iD, Putuma P Gqamana iD, Betty McLean, Jesse Laurey, Daniel Rudy, Jeffrey M McMaster, Y Victoria Zhang

The Journal of Applied Laboratory Medicine · 2024

DOI: 10.1093/jalm/jfae056 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, 2024. Verfasst von Leah Militello und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, United States. Hauptthemen laut MEDLINE: Fentanyl, Tandem Mass Spectrometry. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Fentanyl, a synthetic opioid, has caused many recent overdose deaths. Diagnosis of fentanyl abuse is not served by traditional opiate assays due to differences in chemical structure between synthetics and natural opioids. To our knowledge, this is the first study that uses liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the reference method to evaluate and compare the ARK Fentanyl II Assay (ARK II) and the Fentanyl II Enzyme Immunoassay by Roche (FEN2). The ARK II is designed to detect fentanyl in urine samples, whereas the FEN2 is designed to detect norfentanyl, which is the major metabolite.

Methods

Two hundred patient urine samples including 100 positive and 100 negative samples according to an in-house LC-MS/MS assay were selected for the study. These samples were tested using the ARK II and the FEN2 to determine their performances relative to LC-MS/MS results.

Results

The FEN2 showed a positive and negative predictive value of 100% and 97% and a concordance with LC-MS/MS of 98.5% (kappa 0.97). The ARK II showed a positive and negative predictive value of 100% and 95% and a concordance with LC-MS/MS of 97.5% (kappa 0.95). Additionally, the FEN2 accurately identified 9 positive samples with a range of fentanyl concentrations from 0 to 18 ng/mL for which norfentanyl levels were less than the cutoff of 5 ng/mL, indicating potentially greater sensitivity than otherwise stated.

Conclusions

The FEN2 and the ARK II were evaluated to be similar in terms of positive and negative predictive value during the analysis of 200 patient samples, as well as equally concordant with the LC-MS/MS reference, despite differences in design.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FentanylTandem Mass SpectrometryHumansChromatography, LiquidImmunoassayAnalgesics, OpioidSubstance Abuse DetectionUnited StatesReference StandardsUnited States Food and Drug AdministrationLiquid Chromatography-Mass Spectrometry

Substanzen

FentanylAnalgesics, Opioid

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, United States.

ORCID-Profile: Leah Militello, Putuma P Gqamana

Zitieren

APA

Militello, L., Gqamana, P. P., McLean, B., Laurey, J., Rudy, D., McMaster, J. M., & Zhang, Y. V. (2024). Performance Evaluation of 2 FDA-Approved Fentanyl Immunoassays against LC-MS/MS Reference. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae056

Vancouver

Militello L, Gqamana PP, McLean B, Laurey J, Rudy D, McMaster JM, et al. Performance Evaluation of 2 FDA-Approved Fentanyl Immunoassays against LC-MS/MS Reference. The Journal of Applied Laboratory Medicine. 2024. doi:10.1093/jalm/jfae056

BibTeX
@article{Militello2024,
  author = {Militello, Leah and Gqamana, Putuma P and McLean, Betty and Laurey, Jesse and Rudy, Daniel and McMaster, Jeffrey M and Zhang, Y Victoria},
  title = {Performance Evaluation of 2 FDA-Approved Fentanyl Immunoassays against LC-MS/MS Reference},
  journal = {The Journal of Applied Laboratory Medicine},
  year = {2024},
  doi = {10.1093/jalm/jfae056}
}
Kostenlos starten →